3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA, GA
Inhibikase Therapeutics Dismisses CohnReznick as Independent Auditor
Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
News, Securities Holder Rights or Indentures
Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
Stockholders Approve 2020 Plan Amendment - 3 Million Shares Added
Announces First Quarter 2026 Financial Results and Highlights Recent Activity
Annual Report to Security Holders
Q2
Q1
Q3
Amended Annual Report
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload